Pathology & Oncology Research

, Volume 6, Issue 3, pp 227–232 | Cite as

Occult thyroid pathology in a child with acquired immunodeficiency syndrome

Case report and review of the drug-related pathology in pediatric acquired immunodeficiency syndrome
  • Consolato Sergi
  • Thomas Böhler
  • Günther Schönrich
  • Hauke Sieverts
  • Stephanie U. Roth
  • Klaus-Michael Debatin
  • Herwart F. Otto
Case Report


A 11-year-old boy with acquired immunodeficiency syndrome (AaS), Varicella-zoster virus (VZV) infection and long-term antiviral treatment suffered from a disorder of contractility of the left ventricle of the heart. Following severe unmanageable vomiting, the patient died and the postmortem examination showed marked involution of the lymphatic system, multiple foci of fibrosis of both ventricles of the heart, and regressive changes of the thyroid gland. Biochemical values of the thyroid gland function were, however, not altered. Neither human immunodeficiency virus-related p24 antigen, nor VZV DNA sequences were found in the thyroid gland. Regressive changes of the thyroid gland can probably occur before its function fails. By analyzing the possible etiologies, the endocrine toxicity of a long-term antiviral treatment should be taken into account.


HIV AaS childhood thyroid gland pathology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.2
    Bakshi SS, Britto P, Capparelli E, et al: Evaluation of pharmacokinetics, safety, tolerance, and activity of combinadon of zalcitabine and zidovudine in stable, zidovudinetreated pediatric patients with human immunodeficiency vírus infection. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis 175:1039–1050, 1997.PubMedCrossRefGoogle Scholar
  2. 2.2
    Blumberg BS, Fox RC: The Daedalus effect: changes in ethical questions relating to hepatitis B vírus. Ann Intern Med 102:390–394, 1985PubMedGoogle Scholar
  3. 3.2
    Butler KM, Venzon D, Henry N, et al: Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. Pediatrics 91:747–751, 1993.PubMedGoogle Scholar
  4. 4.2
    Callea F, Fabbretti G, Brisigotti M, et al Valutazione délia patologia da farmaci nel bambino. In: “Farmaci e Bambino. Terapia pediatrica essenziale e principi di farmacologia”. Durand P & Cornaglia-Ferraris P (eds). Casa Editrice Ambrosiana, Milano, 1993, pp. 23–33.Google Scholar
  5. 5.2
    Cohen J: AIDS therapy. Failure isn’t what it used to be…but neither is success. Science 279:1133–1134, 1998.PubMedCrossRefGoogle Scholar
  6. 6.2
    Desai G, Islam R: The changing pattern of surgical pathology of the thyroid gland in Zambia. Cent Afr J Med 38:240–242, 1992.PubMedGoogle Scholar
  7. 7.2
    Domanski MJ, Sloas MM, Follmann DA, et al: Effect of zidovudine and didanosine treatment on heart function in children ínfetted with human immunodeficiency virus. J Pediatr 127:137–146, 1995.PubMedCrossRefGoogle Scholar
  8. 8.2
    Edelman M, Birkenhauer MC, Steinberg J, et al. Microglial nodule encephalitis: limited CNS infection despite disseminated systemic cryptococcosis. Clin Neuropathol 15:30–33, 1996.PubMedGoogle Scholar
  9. 9.2
    Englund JA, Baker CJ, Raskino C, et al: Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 336:1704–1712, 1997.PubMedCrossRefGoogle Scholar
  10. 10.2
    Hannet I, Erkeller-Yuksel F, Lydyard P, et al: Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 13:215–218, 1992.PubMedCrossRefGoogle Scholar
  11. 11.2
    Hirschfeld S: Use of human.recombinant growth hormone and human recombinant insulin-like growth factor-I in patients with human immunodeficiency vírus infection. Horm Res 46:215–221, 1996.PubMedCrossRefGoogle Scholar
  12. 12.2
    Hirschfeld S, Laue L, Cutler GB Jr, et al: Thyroid abnormalities in children infected with human immunodeficiency virus. J Pediatr 128:70–74, 1996.PubMedCrossRefGoogle Scholar
  13. 13.2
    Hoernle EH, Reid TE: Human immunodeficiency vírus infection in children. Am J Health Syst Pharm 52:961–979, 1995.PubMedGoogle Scholar
  14. 14.2
    Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580, 1981.PubMedGoogle Scholar
  15. 15.2
    Joshi VV: Pathology of childhood AIDS. Pediatr Clin North Am 38:97–120, 1991.PubMedGoogle Scholar
  16. 16.2
    Kamali F: Clinical pharmacology of zidovudine and other 2′;3′dideoxynucleoside analogues. Clin Investig 71:392–405, 1993.PubMedCrossRefGoogle Scholar
  17. 17.2
    Keyhani-Rofagha S, Piquero C: Pneumocystis carinii thyroiditis diagnosis by fme needle aspiration cytology: a case report. Acta Cytol 40:307–310, 1996.PubMedGoogle Scholar
  18. 18.2
    Lacaille F, Ortigao MB, Debre M, et al. Hepatic toxicity associated with 2′-3′ dideoxyinosíne in children with AIDS. J Pediatr Gastroenterol Nutr 20:287–290, 1995.PubMedCrossRefGoogle Scholar
  19. 19.2
    Levin TL, Berdon WE, Tang HB, et al: Dideoxyinosine-induced pancreatitis in human immunodeficiency vírus-infected children. Pediatr Radiol 27:189–191, 1997.PubMedCrossRefGoogle Scholar
  20. 20.2
    Luzuriaga K, Bryson Y, McSherry G, et al: Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 174:713–721, 1996.PubMedGoogle Scholar
  21. 21.2
    Matarazzo P, Palomba E, Lala R, et al: Tovo PA: Growth impairment, IGF I hyposecretion and thyroid dysfunction in children with perinatal HIV-1 infection. Acta Paediatr 83:1029–1034, 1994.PubMedCrossRefGoogle Scholar
  22. 22.2
    Mueller BU, Butler KM, Stocker VL, et al: Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics 94:724–731, 1994.PubMedGoogle Scholar
  23. 23.2
    Pizzo PA, Butler K, Balis F, et al: Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency vírus infection. J Pediatr 117:799–808, 1990.PubMedCrossRefGoogle Scholar
  24. 24.2
    Puchhammer-Stöckl E: PCR detection of varicella zoster vírus. In: Persing DH, Snith TF, Tenover FC, White TJ (eds). Diagnostic molecular microbiology. Principles and applications. American Society for Microbiology, Washington, 1993, pp. 356–360.Google Scholar
  25. 25.2
    Schwartz LJ, St Louis Y, Wu R, et al: P: Endocrine function in children with human immunodeficiency vírus infection. Am J Dis Child 145:330–333, 1991.PubMedGoogle Scholar
  26. 26.2
    Sergi C, Böhler T, Schönrich G, et al: Pediatric Acquired Immunodeficiency Syndrome (PAIDS) as viewed by the pathologist and the immunologist: up-dated review. Pediatr Grenzgeb (Pediatrics and related topics) 37:271–332, 1998.Google Scholar
  27. 27.2
    Whitcup SM, Dastgheib K, Nussenblatt RB, et al: A clinicopathologic report of the retinal lesions associated with didanosine. Arch Ophthalmol 112:1594–1598, 1994.PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2000

Authors and Affiliations

  • Consolato Sergi
    • 1
  • Thomas Böhler
    • 2
  • Günther Schönrich
    • 3
  • Hauke Sieverts
    • 4
  • Stephanie U. Roth
    • 5
  • Klaus-Michael Debatin
    • 2
  • Herwart F. Otto
    • 1
  1. 1.Institute of PathologyUniversity of HeidelbergHeidelbergGermany
  2. 2.Department of PediatricsUniversity of UlmHeidelbergGermany
  3. 3.Institute of Hygiene and MicrobiologyUniversity of HeidelbergHeidelbergGermany
  4. 4.Department of PediatricsUniversity of HeidelbergHeidelbergGermany
  5. 5.Department of NeuropathologyUniversity of HeidelbergHeidelbergGermany

Personalised recommendations